Please check your internet connection and try again.
# Walethmade bromide
## Overview
"Walethmade bromide" is not a recognized pharmaceutical agent. It is likely a misspelling or an erroneous chemical string. The most probable intended drug is **Glycopyrrolate bromide** (an anticholinergic/antimuscarinic agent). The information below refers to Glycopyrrolate.
## Primary Indications
* Reduction of secretions (sialorrhea, intraoperative airway secretions).
* Reversal of neuromuscular blockade (with neostigmine).
* Peptic ulcer disease (adjunctive therapy, historically).
## Adult Dosing
* **Secretions:** 0.1 mg to 0.2 mg IM/IV every 3–4 hours as needed.
* **Anesthesia Premedication:** 0.004 mg/kg IM (up to 0.2 mg) 30–60 minutes prior to induction.
* **Neuromuscular Blockade Reversal:** 0.2 mg for every 1 mg of neostigmine administered.
## Pediatric Dosing
* **Secretions (Intraoperative):** 0.004–0.01 mg/kg IV/IM; do not exceed 0.2 mg/dose.
* **Children/Adolescents (Chronic Sialorrhea - Oral Solution):** Dosing is weight-based (typically 0.02 mg/kg to 0.1 mg/kg) per institutional/product-specific protocol; titration is required due to risk of systemic anticholinergic toxicity.
## Dose Adjustments
* **Renal Impairment:** Use with caution. Glycopyrrolate is primarily renally excreted. Monitor for prolonged muscarinic blockade.
* **Hepatic Impairment:** No specific guidelines; use caution due to altered metabolism/excretion.
## Contraindications
* Hypersensitivity to the drug.
* Tachycardia secondary to cardiac insufficiency or thyrotoxicosis.
* Obstructive uropathy (e.g., prostatic hypertrophy).
* Paralytic ileus or toxic megacolon.
* Severe ulcerative colitis or obstructive GI disease.
* Myasthenia gravis (unless used for anticholinergic side effects of cholinesterase inhibitors).
## Adverse Effects
* **Common:** Xerostomia (dry mouth), constipation, urinary retention, blurred vision (mydriasis/cycloplegia), tachycardia.
* **Serious:** Heat prostration (decreased sweating), confusion/hallucinations (central anticholinergic syndrome), arrhythmias, anaphylaxis.
## Key Drug Interactions
* **Potentiation:** Increased anticholinergic effect when combined with antihistamines, tricyclic antidepressants, phenothiazines, and amantadine.
* **Absorption:** May decrease absorption of concurrently administered oral medications due to delayed gastric emptying.
## Monitoring
* Heart rate (monitor for drug-induced tachycardia).
* Urinary output (monitor for retention).
* GI motility (monitor for constipation or obstructive symptoms).
* Mental status (monitor for CNS toxicity in elderly or pediatric populations).
## Clinical Pearls
* Glycopyrrolate is a quaternary ammonium compound; unlike atropine, it does not readily cross the blood-brain barrier. Consequently, it has fewer CNS side effects than tertiary amines (like atropine or scopolamine).
* Always verify the concentration of the vial/solution, as dosing errors regarding decimal places can lead to significant overdose.
* If the user intended a different agent, please clarify the spelling or provide the brand name.
***
**Educational Disclaimer:** This information is for educational purposes only and does not constitute medical advice. Pharmacological data can change; always verify dosing, contraindications, and drug interactions against institutional protocols and current clinical sources such as the FDA-approved package insert or recognized drug information databases (e.g., Lexicomp, Micromedex) before prescribing or administering medication.
